Cryoport vs OmniAb
Cryoport reported revenue of $176 million in fiscal 2025, 9.4 times OmniAb's $19 million in fiscal 2025. Cryoport's revenue grew 12.4% in its latest year, and OmniAb's fell 29.3%. Cryoport had an operating margin of -20.9%, against -369.5% at OmniAb. Free cash flow was −$25 million at Cryoport and −$37 million at OmniAb.
Side by side
| Cryoport | OmniAb | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $176M | $19M |
| Revenue growth | 12.4% | −29.3% |
| Revenue growth a year, last 5 years | 17.5% | — |
| Gross margin | 47.1% | — |
| Operating margin | −20.9% | −369.5% |
| Net margin | 44.4% | −347.0% |
| Free cash flow | −$25M | −$37M |
| Free cash flow margin | −14.2% | −198.3% |
| Return on capital | −23.4% | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $10M | $0M |
| Change in diluted share count | 1.5% | 11.0% |
| Last close | $19.89 | $4.91 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | — |
| Piotroski F-score | 4 of 9 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
CryoportOmniAb
Operating margin
Percent of revenue
CryoportOmniAb
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
CryoportOmniAb